The convalescent plasma roller coaster
The FDA's about-face on emergency approval of convalescent plasma raises questions about the level of evidence we need for Covid-19 treatments, and the role of politics in these decisions. More
Will it take 50-100 years to get the right answer about tPA for stroke?
Do the potential benefits of thrombolytic drugs for acute stroke outweigh the potential harms? In a guest blog, Drs W. Ken Milne and Daniel Fatovich examine this issue in light of new evidence. More
Key questions about remdesivir still unanswered
Since the release of the initial NIH study results, clinicians and researchers have posed many questions about remdesivir, which have so far gone unanswered. Here are a few of them... More
Why pandemic science has gone out of control
In "Issues in Science and Technology," Shannon Brownlee and Jeanne Lenzer explain how our toxic legacy of bad science in medicine has affected coronavirus research. More
Coronavirus treatment hype can lead to harm
Is hydroxychloroquine a "miracle cure" for COVID-19? Or just unwarranted hype? More
No evidence for common bladder pain treatments, patient advocates find
Doctors are increasingly recognizing that bladder pain and urgency is often a symptom of a larger problem with many potential causes. But has this recognition translated into change of practice? More
New Alzheimer’s drug: Game-changing or underwhelming?
When it comes to dementia and Alzheimer's Disease, it appears that anxiety about cognitive decline is driving treatment decisions, rather than evidence. More
The RCT blind spot
Randomized controlled trials are known as the "gold standard" in medical research--but they also have a significant down-side... More
Research on overuse harms: Where do we go from here?
How do we frame overuse not just as an issue of cost but also as an issue of harm? A recap of the Lown Institute meeting on overuse harms research. More
The top ten overuse studies of 2018
Which studies on overuse in 2018 were the most influential? More